Skip to main content
Biogen10-Q: Compliance burden

IRA Medicare Part D redesign creates $90.0 million unfavorable net impact on 2025 revenue

Source: Autobound Signal API · 74 signals tracked for Biogen · updated

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.

What happened

The IRA's drug pricing controls and Medicare Part D redesign had an adverse impact on sales, creating a net unfavorable impact of approximately $90.0 million to full-year 2025 revenue, concentrated in SKYCLARYS and MS products.

Source

SEC EDGARApr 29, 2026

Quarterly report (Form 10-Q)

Biogen 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

The IRA Medicare Part D redesign had a modest net unfavorable impact to our full-year 2025 revenue of approximately $90.0 million, concentrated in our SKYCLARYS and MS portfolio product revenue, approximately a quarter of which was associated with SKYCLARYS.

sec.gov/Archives/edgar/data/875045/000087504526000045/biib-20260331.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Compliance burden

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
Apr 29, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$90M (unfavorable impact to full-year 2025 revenue from IRA Medicare Part D redesign)

Details

CIK
875045
Accession number
0000875045-26-000045
Timeframe
Last year
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
GRC tools needed
Signal category
Risk

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
80%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
complianceBurden

Use this data

Get every 10-Q signal for Biogen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/4acd6b40-56b2-41e7-9389-400fbf5ea1b0 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.

{
  "signal_id": "4acd6b40-56b2-41e7-9389-400fbf5ea1b0",
  "signal_type": "sec-10q",
  "signal_subtype": "complianceBurden",
  "detected_at": "2026-11-09T06:24:49.483+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "detail": "The IRA's drug pricing controls and Medicare Part D redesign had an adverse impact on sales, creating a net unfavorable impact of approximately $90.0 million to full-year 2025 revenue, concentrated in SKYCLARYS and MS products. Healthcare compliance and commercial strategy vendors may find opportunities to help optimize revenue management and regulatory reporting under shifting pricing mandates.",
    "metrics": {
      "timeframe": "last_year",
      "dollar_context": "unfavorable impact to full-year 2025 revenue from IRA Medicare Part D redesign",
      "dollar_millions": 90
    },
    "quarter": "Q1",
    "summary": "IRA Medicare Part D redesign creates $90.0 million unfavorable net impact on 2025 revenue",
    "excerpts": "The IRA Medicare Part D redesign had a modest net unfavorable impact to our full-year 2025 revenue of approximately $90.0 million, concentrated in our SKYCLARYS and MS portfolio product revenue, approximately a quarter of which was associated with SKYCLARYS.",
    "relevance": 0.8,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000045/biib-20260331.htm",
    "filing_date": "2026-04-29",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "GRC tools needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.